Assessment of the absorption, metabolism and excretion of [14C]pasireotide in healthy volunteers using accelerator mass spectrometry

Tolerability and Dose Proportional Pharmacokinetics of Pasireotide Administered as a Single Dose or Two Divided Doses in Healthy Male Volunteers: A Single-Center, Open-Label, Ascending-Dose Study

(2012) Stephan Petersenn et al.   CLINICAL THERAPEUTICS

Effect of Hepatic Impairment on the Pharmacokinetics of Pasireotide (SOM230): Results From a Multicenter Phase I Study

(2012) Yves Horsmans et al.   JOURNAL OF CLINICAL PHARMACOLOGY

A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers

(2012) Georg Golor et al.   Drug Design Development and Therapy

Pasireotide (SOM230), a Novel Multireceptor-Targeted Somatostatin Analogue, Is Well Tolerated When Administered as a Continuous 7-Day Subcutaneous Infusion in Healthy Male Volunteers

(2011) Stephan Petersenn et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Pasireotide (SOM230) Demonstrates Efficacy and Safety in Patients with Acromegaly: A Randomized, Multicenter, Phase II Trial

(2010) S. Petersenn et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Accelerator mass spectrometry-enabled studies: current status and future prospects

(2010) Ali Arjomand   Bioanalysis